381 related articles for article (PubMed ID: 12769619)
1. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
Chavez-Noriega LE; Schaffhauser H; Campbell UC
Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
[TBL] [Abstract][Full Text] [Related]
2. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
[TBL] [Abstract][Full Text] [Related]
3. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
Maksymetz J; Moran SP; Conn PJ
Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
DD DD; Marek GJ
Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):215-25. PubMed ID: 12769628
[TBL] [Abstract][Full Text] [Related]
5. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
Kanuma K; Aoki T; Shimazaki Y
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
Dogra S; Conn PJ
Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
8. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Chaki S
Eur J Pharmacol; 2010 Aug; 639(1-3):59-66. PubMed ID: 20371240
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
10. The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat.
Gastambide F; Gilmour G; Robbins TW; Tricklebank MD
Neuropharmacology; 2013 Jan; 64():240-7. PubMed ID: 22884612
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
[TBL] [Abstract][Full Text] [Related]
12. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
Chaki S; Yoshida S; Okuyama S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
[TBL] [Abstract][Full Text] [Related]
13. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
[TBL] [Abstract][Full Text] [Related]
14. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
[TBL] [Abstract][Full Text] [Related]
15. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
Chaki S; Hikichi H
Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
[TBL] [Abstract][Full Text] [Related]
16. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists.
Swanson CJ; Schoepp DD
Ann N Y Acad Sci; 2003 Nov; 1003():309-17. PubMed ID: 14684454
[TBL] [Abstract][Full Text] [Related]
17. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease.
Williams CJ; Dexter DT
J Neurochem; 2014 Apr; 129(1):4-20. PubMed ID: 24224472
[TBL] [Abstract][Full Text] [Related]
19. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Lorrain DS; Schaffhauser H; Campbell UC; Baccei CS; Correa LD; Rowe B; Rodriguez DE; Anderson JJ; Varney MA; Pinkerton AB; Vernier JM; Bristow LJ
Neuropsychopharmacology; 2003 Sep; 28(9):1622-32. PubMed ID: 12825094
[TBL] [Abstract][Full Text] [Related]
20. The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801.
Vales K; Svoboda J; Benkovicova K; Bubenikova-Valesova V; Stuchlik A
Eur J Pharmacol; 2010 Aug; 639(1-3):91-8. PubMed ID: 20371226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
